Literature DB >> 12843008

Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses.

Yevgeniy Y Studentsov1, Gloria Y F Ho, Morgan A Marks, Robert Bierman, Robert D Burk.   

Abstract

Human papillomavirus type 16 (HPV16) virus-like particles (VLP) were used as antigen in a polymer enzyme-linked immunosorbent assay (ELISA) to measure antibodies to HPV capsid proteins. Serum samples from 575 college women, previously tested for the presence of cervicovaginal HPV DNA, were analyzed. The prevalences of anti-HPV16 VLP antibodies at baseline were 14.1% for immunoglobulin G (IgG) and 6.4% for IgA. The seroprevalences of IgG in women with cervicovaginal HPV16, HPV16-related types, and other HPV types were 55, 33, and 19%, respectively (P < 0.001), compared to the prevalence in women without an HPV infection (10%). HPV VLP IgA seropositivity was associated with high HPV16 VLP IgG optical density values. The seropositivity of IgG antibodies was independently associated with infection with HPV16 or HPV16-related types, increased number of lifetime male partners for vaginal sex, having sex with men >/= 5 years older, history of abnormal PAP smear, older age, and living separately from parents. Use of HPV16 VLP polymer ELISA detects clade-specific responses and suggests an HPV16 VLP vaccine may have broader protection that initially anticipated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843008      PMCID: PMC165285          DOI: 10.1128/JCM.41.7.2827-2834.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

1.  The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop.

Authors: 
Journal:  JAMA       Date:  1989-08-18       Impact factor: 56.272

2.  Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes.

Authors:  A Touzé; S de Sanjosé; P Coursaget; M R Almirall; V Palacio; C J Meijer; J Kornegay; F X Bosch
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

3.  Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus.

Authors:  Yevgeniy Y Studentsov; Mark Schiffman; Howard D Strickler; Gloria Y F Ho; Yuk-Ying Susana Pang; John Schiller; Rolando Herrero; Robert D Burk
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids.

Authors:  Z H Wang; L Kjellberg; H Abdalla; F Wiklund; C Eklund; P Knekt; M Lehtinen; I Kallings; P Lenner; G Hallmans; C G Mählck; G Wadell; J Schiller; J Dillner
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

5.  Human papillomavirus infection in sexually active adolescent females: prevalence and risk factors.

Authors:  A B Moscicki; J Palefsky; J Gonzales; G K Schoolnik
Journal:  Pediatr Res       Date:  1990-11       Impact factor: 3.756

6.  Human papillomavirus infection of the cervix detected by cervicovaginal lavage and molecular hybridization: correlation with biopsy results and Papanicolaou smear.

Authors:  R D Burk; A S Kadish; S Calderin; S L Romney
Journal:  Am J Obstet Gynecol       Date:  1986-05       Impact factor: 8.661

7.  Genital human papillomavirus infection in female university students as determined by a PCR-based method.

Authors:  H M Bauer; Y Ting; C E Greer; J C Chambers; C J Tashiro; J Chimera; A Reingold; M M Manos
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

8.  Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

Authors:  J Zhou; X Y Sun; D J Stenzel; I H Frazer
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

9.  Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

Authors:  Gloria Y F Ho; Yevgeniy Studentsov; Charles B Hall; Robert Bierman; Leah Beardsley; Michele Lempa; Robert D Burk
Journal:  J Infect Dis       Date:  2002-08-28       Impact factor: 5.226

10.  Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies.

Authors:  N D Christensen; R Höpfl; S L DiAngelo; N M Cladel; S D Patrick; P A Welsh; L R Budgeon; C A Reed; J W Kreider
Journal:  J Gen Virol       Date:  1994-09       Impact factor: 3.891

View more
  7 in total

Review 1.  Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.

Authors:  Sarah M Tiggelaar; Margaret J Lin; Raphael P Viscidi; Jia Ji; Jennifer S Smith
Journal:  J Adolesc Health       Date:  2012-02       Impact factor: 5.012

2.  Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.

Authors:  Dianne J Marais; Debbie Constant; Bruce Allan; Henri Carrara; Margaret Hoffman; Samuel Shapiro; Chelsea Morroni; Anna-Lise Williamson
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

3.  Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.

Authors:  Koenraad Van Doorslaer; Laura L Reimers; Yevgeniy Y Studentsov; Mark H Einstein; Robert D Burk
Journal:  Gynecol Oncol       Date:  2009-06-24       Impact factor: 5.482

4.  Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women.

Authors:  Jia Ji; Hai-Kui Sun; Jennifer S Smith; He Wang; Mark T Esser; Shangying Hu; Robert G Pretorius; Wen Chen; Jerome L Belinson; You-Lin Qiao
Journal:  BMC Infect Dis       Date:  2012-06-20       Impact factor: 3.090

5.  The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population.

Authors:  Freddy Sitas; Margaret Urban; Lara Stein; Valerie Beral; Paul Ruff; Martin Hale; Moosa Patel; Dianne O'Connell; Xue Qin Yu; Anke Verzijden; Dianne Marais; Anna-Lise Williamson
Journal:  Infect Agent Cancer       Date:  2007-03-02       Impact factor: 2.965

6.  More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population.

Authors:  Dianne J Marais; Candice Sampson; Anthea Jeftha; Dherendra Dhaya; Jo-Ann S Passmore; Lynette Denny; Edward P Rybicki; Eric Van Der Walt; Lawrence Xg Stephen; Anna-Lise Williamson
Journal:  BMC Infect Dis       Date:  2006-06-08       Impact factor: 3.090

7.  Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection.

Authors:  Ana Gradissimo; Viswanathan Shankar; Fanua Wiek; Lauren St Peter; Yevgeniy Studentsov; Anne Nucci-Sack; Angela Diaz; Sarah Pickering; Nicolas F Schlecht; Robert D Burk
Journal:  Viruses       Date:  2021-08-05       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.